Pliant Therapeutics (PLRX) Assets Average (2020 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Assets Average of $213.9 million for Q1 2026, down 42.32% year-over-year from $370.9 million in Q1 2025, and down 14.75% quarter-over-quarter from $250.9 million in Q4 2025.
Pliant Therapeutics (PLRX) Assets Average (2020 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Assets Average for 7 consecutive years, with $213.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 42.32% year-over-year to $213.9 million; the TTM figure through Mar 2026 stood at $213.9 million (down 42.32% YoY), while the FY2025 annual figure was $311.1 million, down 31.56% from the prior year.
- Assets Average declined to $213.9 million in Q1 2026 per PLRX's latest filing, from $250.9 million in the prior quarter.
- Across five years, Assets Average topped out at $586.4 million in Q2 2023 and bottomed at $190.8 million in Q2 2022.
- Historically, Assets Average has averaged $384.8 million across 5 years, with a median of $370.9 million in 2025.
- Annual changes were most pronounced in 2023 — Assets Average soared 207.3% — and 2026, when it sank 42.32%.
- Pliant Therapeutics' Assets Average stood at $363.9 million in 2022, then soared by 44.63% to $526.3 million in 2023, then slipped by 19.95% to $421.3 million in 2024, then tumbled by 40.44% to $250.9 million in 2025, then dropped by 14.75% to $213.9 million in 2026.
- Business Quant data shows PLRX's Assets Average at $213.9 million in Q1 2026, $250.9 million in Q4 2025, and $288.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Pliant Therapeutics | 70.59 Mn | 70.59 Mn | - | 196.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 196.24 Mn |
| Mar 31, 2026 | 213.91 Mn |
| Dec 31, 2025 | 250.91 Mn |
| Sep 30, 2025 | 288.21 Mn |
| Jun 30, 2025 | 322.30 Mn |
| Mar 31, 2025 | 370.86 Mn |
| Dec 31, 2024 | 421.31 Mn |
| Sep 30, 2024 | 464.70 Mn |
| Jun 30, 2024 | 502.67 Mn |
| Mar 31, 2024 | 516.88 Mn |
| Dec 31, 2023 | 526.31 Mn |
| Sep 30, 2023 | 557.68 Mn |
| Jun 30, 2023 | 586.39 Mn |
| Mar 31, 2023 | 474.25 Mn |
| Dec 31, 2022 | 363.90 Mn |
| Sep 30, 2022 | 280.90 Mn |
| Jun 30, 2022 | 190.82 Mn |
| Mar 31, 2022 | 209.12 Mn |
| Dec 31, 2021 | 227.67 Mn |
| Sep 30, 2021 | 244.92 Mn |